BMY
NYSEBristol-Myers Squibb Company
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks109-27%
2025-12-072026-05-31
Mix6190d
- Other28(46%)
- Insider22(36%)
- SEC Filings7(11%)
- Earnings3(5%)
- Leadership1(2%)
Latest news
25 items- PRIzalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Breast Cancer and Esophageal Squamous Cell CarcinomaInterim analyses from PANKU-Breast02 (BL-B01D1-307) and PANKU-Esophagus01 (BL-B01D1-305) presented at ASCO® 2026 SystImmune and Bristol Myers Squibb's potent dual-targeted EGFRxHER3 bispecific antibody-drug conjugate has now demonstrated clinical benefit in three Phase 3 trials in China, underscoring its broad therapeutic potential in multiple tumor types SystImmune, Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb (NYSE:BMY) today announced that SystImmune's parent company, Sichuan Biokin Pharmaceutical Co., Ltd. (Biokin), reported positive results from prespecified interim analyses of two Phase 3 studies evaluating izalontamab brengitecan (iza-bren),
- PRU.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)Camzyos has the potential to be the first pharmacological therapy for the treatment of oHCM in adolescents, addressing a high unmet need for this population Application based on positive results of Phase 3 SCOUT-HCM trial, which met its primary endpoint with safety profile similar to established profile in adults Bristol Myers Squibb (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Camzyos (mavacamten) as a potential treatment for adolescents (ages 12 years to <18 years) with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). If approved, Camzyos would be the first cardiac myosin inhibitor (CMI) to tr
- PRBristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin LymphomaFirst-ever immunotherapy combination approved in Europe for adult and adolescent patients, ages 12 and older, with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL) Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission (EC) has approved Opdivo® (nivolumab) in combination with doxorubicin, vinblastine and dacarbazine (AVD) for the treatment of adult and adolescent patients 12 years of age and older with previously untreated Stage III or IV classical Hodgkin Lymphoma (cHL). This approval marks a significant milestone, establishing the Opdivo plus AVD combination as the first immunotherapy-based regimen available in the European Union (EU) for newly
- PRGlobal Data for BioNTech and Bristol Myers Squibb's PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 TrialFirst investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 expression levels and subtypes, highlighting its potential to set a new standard of carePumitamig plus chemotherapy showed robust and consistent antitumor activity in first-line non-small cell lung cancer at both evaluated dose levels, with higher confirmed objective response rates at the lower dose of 63.6% in the non-squamous and 72.7% in the squamous subtypesPumitamig is advancing through a comprehensive global Phase 3 development program in non-small cell lung cancer, including the actively
- PRBristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple MyelomaFirst Phase 3 results for a CELMoD presented as late-breaking presentation at ASCO® 2026 SUCCESSOR-2 data reinforce the potential of CELMoD therapies to transform outcomes for patients with RRMM Bristol Myers Squibb (NYSE:BMY) today announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of CELMoD (cereblon E3 ligase modulation) mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM). Results showed MeziKd demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS) (95% CI: 1
- PRBristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBristol Myers Squibb (NYSE:BMY) today announced that the company will participate in the Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9, 2026. The company will take part in a fireside chat beginning at 2:00 p.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what's p
- PRBristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation PipelineLate-breaking Phase 3 SUCCESSOR-2 study results highlight potential of mezigdomide, a novel CELMoD from the Company's targeted protein degradation platform, in relapsed or refractory multiple myeloma Additional data from the Company's differentiated pipeline including pumitamig, iza-bren, iberdomide and golcadomide to also be presented at meeting Bristol Myers Squibb (NYSE:BMY) today announced the presentation of data from its oncology portfolio and pipeline at the 2026 American Society of Clinical Oncology (ASCO®) Annual Meeting to be held May 29 – June 2 in Chicago, Illinois. Across more than 60 disclosures and 19 oral presentations, the Company will highlight progress from its differ
- PRBristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global OperationsThe collaboration brings together BMS' deep scientific expertise and Anthropic's frontier AI to accelerate the discovery, development and delivery of transformational medicines BMS will deploy Claude's agentic capabilities, moving beyond conversational AI, to connect its people, systems and institutional knowledge at enterprise scale Bristol Myers Squibb (NYSE:BMY, ", BMS", )), a global biopharmaceutical leader, today announced a strategic agreement with Anthropic to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functions. The collaboration signals a meaningful evolution in how BMS deploys AI, moving beyond conversational too
- PRTempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and NeuroscienceTempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE:BMY). This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs. With Lens, Tempus' AI-enabled analytical platform, BMS and Tempus are applying insights from a vast library of de-identified multimodal records to optimize clinical research and strengthen PTRS across BMS' development portfolio. This collaboration combines unprecedented sc
- PRPacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board NomineesHighlights Nominees' Robust Skillsets and Extensive Experience in Healthcare and Biopharmaceuticals Urges Stockholders to Vote "FOR" the Election of Pacira's Highly Qualified Nominees on the BLUE Proxy Card Today BRISBANE, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) (the "Company" or "Pacira"), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has sent a letter to stockholders in connection with its upcoming 2026 Annual Meeting of Stockholders (the "Annual Meeting"), scheduled to be held on June 9, 2026. Stockholders of record as of April 22, 2026 are entit
- PRWall Street's Cardiac Bet: Where Diagnostics Meet the MoneyISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.USANewsGroup.com News CommentaryVANCOUVER, BC, May 12, 2026 /CNW/ -- Cardiovascular disease is about to become the most expensive problem in American medicine. The American Heart Association fired a warning shot in late April: U.S. heart disease costs are on pace to quadruple by 2050, and total national healthcare spending is already closing in on $5 trillion a year[1]. That kind of structural pressure is forcing hospitals to rethink how they diagnose and treat cardiac patients, and the money is following. The global AI cardiology market, valued at $2.78 billion this year, is projected to reach over $14 billion by 2034 as health systems race to
- SECSEC Form S-8 filed by Bristol-Myers Squibb CompanyS-8 - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
- SECBristol-Myers Squibb Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
- PRBristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in AdultsIn the pivotal Phase 3 POETYK PsA clinical trials, Sotyktu demonstrated superiority compared with placebo at Week 16 across multiple endpoints, including skin and joint symptoms, with improvements in quality of life as reflected in the European Union Summary of Product Characteristics (SmPC) Sotyktu, a once-daily oral treatment, is the first and only tyrosine kinase 2 (TYK2) inhibitor to be approved in the European Union for this indication Bristol Myers Squibb (NYSE:BMY) today announced that the European Commission has granted approval to Sotyktu (deucravacitinib), alone or in combination with methotrexate, for the treatment of active psoriatic arthritis (PsA) in adults who have had an
- PRBristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026Bristol Myers Squibb (NYSE:BMY) today announced that the company will present at the Bank of America Securities Healthcare Conference 2026 on Thursday, May 14, 2026. The company will take part in a fireside chat beginning at 8:40 a.m. PT/11:40 a.m. ET. Investors and the general public are invited to listen to the session by visiting http://investor.bms.com. An archived edition of the session will be available following its conclusion. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to defin
- INSIDEREVP, Chief Commercial Officer Lenkowsky Adam converted options into 1,373 shares, disposed of 203 shares and covered exercise/tax liability with 599 shares, increasing direct ownership by 3% to 19,706 units (SEC Form 4)4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)
- PRBristol Myers Squibb Launches "Won't Lose" Media Campaign Ahead of FIFA World Cup 2026™Campaign Highlights BMS' Relentless Drive to Advance Breakthroughs for Patients Bristol Myers Squibb (NYSE:BMY) today announced the launch of "Won't Lose," a new campaign debuting ahead of the FIFA World Cup 2026™. Leveraging a major cultural and global moment, the "Won't Lose" campaign showcases the relentless mindset that drives Bristol Myers Squibb's work every day, pushing bold science forward for patients who cannot wait. The "Won't Lose" mantra embodies the fight, fire and focus that defines BMS, relentlessly advancing breakthrough medicines for patients. The campaign is a pledge to give everything for the patients who depend on BMS and its medicines, and to demonstrate the urgency
- SECSEC Form 10-Q filed by Bristol-Myers Squibb Company10-Q - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
- SECBristol-Myers Squibb Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
- PRBristol Myers Squibb Reports First Quarter Financial Results for 2026Bristol Myers Squibb (NYSE:BMY) today reported first quarter 2026 financial results. Visit the company's Investor Relations website at http://investor.bms.com to view the detailed first quarter 2026 earnings press release and investor presentation. The company will host a conference call and live audio webcast for analysts and investors at 8:00 a.m. ET today, April 30, 2026, which is accessible here. Company executives will review financial results with the investment community during the call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Th
- PRBristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug CompanyExpands Options for Cash-Paying Patients to Access the Nation's #1 Prescribed Oral Blood Thinner The Bristol Myers Squibb-Pfizer (NYSE:BMY) — (NYSE:PFE) Alliance today announced the launch of a collaboration with Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) to offer Eliquis® (apixaban) on CostPlusDrugs.com. Eliquis is one of the most widely prescribed oral anticoagulants in the United States and one of the largest brands in the space to be offered on the site, which allows patients to purchase prescription medicines directly at reduced costs, providing another avenue for patients to access the medication. "The BMS-Pfizer Alliance is pleased to expand our direct-to-patient options
- PRAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationSAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (NASDAQ:RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics directly to the heart, announced today it has earned a $15 million development milestone payment from Bristol Myers Squibb (NYSE:BMY). The milestone was achieved upon the successful delivery of a development candidate for the first licensed compound targeting a cardiology indication under the Company's ongoing collaboration. "This milestone marks a meaningful step forward for Atrium, further expanding our RNA deliv
- PRFoundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP DeletionFoundation Medicine, Inc., a global precision medicine company, today announced an expansion to its collaboration with Bristol Myers Squibb (NYSE:BMY) to develop FoundationOne®CDx as a next-generation sequencing-based companion diagnostic to identify patients with homozygous MTAP deletion in multiple indications for an investigational targeted therapy. The expansion broadens Foundation Medicine's longstanding relationship in advancing biomarker-driven therapies with Bristol Myers Squibb. Homozygous deletion is a major cause of MTAP deficiency.1 Copy number calling can have low signal-to-noise ratio, making the alterations challenging to accurately identify. FoundationOne CDx is a tissue-b
- PRArdelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal OfficerWALTHAM, Mass., April 20, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant unmet medical needs, today announced the appointment of Felecia W. Ettenberg, a seasoned leader with more than 25 years of legal experience in the biopharmaceutical industry, as Chief Legal Officer (CLO). She will oversee Ardelyx's legal, compliance, regulatory, and government affairs operations. Ms. Ettenberg succeeds Elizabeth Grammer, who has chosen to retire after an extraordinary 16-year career at the company. "I am thrilled to welcome Felecia as our new Chief Legal Officer," said Mik
- SECSEC Form DEFA14A filed by Bristol-Myers Squibb CompanyDEFA14A - BRISTOL MYERS SQUIBB CO (0000014272) (Filer)
BMY FAQ
6 questionsWhat does Bristol-Myers Squibb Company do?
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and...Where does BMY stock trade?
Bristol-Myers Squibb Company (BMY) is listed on NYSE.What sector and industry is BMY in?
Bristol-Myers Squibb Company operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about BMY?
Bristol-Myers Squibb Company has had 8 recent analyst actions on file. The most recent action was from RBC Capital Mkts: Sector Perform on 2026-02-25. Recent price targets range from $4200.00 to $4500.00.What companies are similar to BMY?
Notable peers in the same industry include AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare BMY side-by-side with any of them on Quantisnow.How can I track BMY on Quantisnow?
Quantisnow aggregates Bristol-Myers Squibb Company's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BMY to receive live email and push alerts on every new disclosure.